IOVS Am. J. Clin. Nutrition
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2003;44:3586-3592.)
© 2003 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.03-0038
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Espinosa-Heidmann, D. G.
Right arrow Articles by Cousins, S. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Espinosa-Heidmann, D. G.
Right arrow Articles by Cousins, S. W.

Macrophage Depletion Diminishes Lesion Size and Severity in Experimental Choroidal Neovascularization

Diego G. Espinosa-Heidmann,1 Ivan J. Suner,1 Eleut P. Hernandez,1 Dagoberto Monroy,1 Karl G. Csaky,2 and Scott W. Cousins1

1From the Bascom Palmer Eye Institute, Department of Ophthalmology, The University of Miami School of Medicine, Miami, Florida; and the 2National Eye Institute, National Institutes of Health, Bethesda, Maryland.


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
PURPOSE. Macrophage recruitment to the choroid has been proposed to contribute to the pathogenesis of choroidal neovascularization (CNV) in AMD. The study was conducted to determine whether treatment with clodronate liposomes (CL2MDP-lip), which cause depletion of blood monocytes and lymph node macrophages, diminishes the severity of neovascularization in a mouse model of laser-induced CNV.

METHODS. Laser-induced CNV was performed in female 16-month-old C57BL/6 mice. Macrophages were depleted by use of CL2MDP-lip intraperitoneally and subcutaneously 72 and 24 hours before and every 2 to 3 days after laser injury. Control mice received injections of either PBS alone or PBS liposomes. Blood monocyte and choroidal macrophage depletion were documented by flow cytometry and choroidal flatmount preparation analysis, respectively. Two weeks after laser injury, mice were injected intravenously with fluoresceinated dextran. The right eyes were removed and prepared for flatmount analysis of CNV surface area (in relative disc areas or DA), vascularity (relative fluorescence), and cellularity (propidium iodide stain). The mice were then perfused with 10% formaldehyde, and the left eyes were removed for histopathology. The means of the various parameters for four CNV lesions per eye were calculated. Fluorescein angiography was also performed.

RESULTS. Flow cytometry of circulating monocytes and immunohistochemical analysis of choroidal macrophage density confirmed the effective depletion of blood monocytes and choroidal macrophages respectively in CL2MDP-lip–treated mice. Compared with the control, flatmount analysis of macrophage depleted mice demonstrated a significant reduction in size of the CNV area (2.8 ± 0.5 DA vs. 1.4 ± 0.1 DA; P < 0.043). The treated group also revealed less vascularity (1.6 ± 0.1 units vs. 1.1 ± 0.0 units; P < 0.0092) and cellularity of CNV lesions (3.3 ± 0.6 DA vs. 1.7 ± 0.1 DA, P < 0.04). Histopathology revealed that, in the macrophage-depleted group, CNV was smaller in diameter (1270 ± 73 pixels vs. 770 ± 82 pixels, P < 0.0006) and thickness (120 ± 7 pixels vs. 96 ± 7 pixels, P < 0.019).

CONCLUSIONS. Macrophage depletion using CL2MDP-lip reduces size, cellularity, and vascularity of CNV. This observation supports the hypothesis that macrophages contribute to the severity of CNV lesions.

Choroidal neovascularization (CNV) is the major vision-threatening complication associated with several common retinal degenerative or inflammatory diseases, especially age-related macular degeneration (AMD).1 2 3 The pathogenesis of neovascular AMD is clearly multifactorial, with age, systemic health, genetic, and environmental risk factors playing roles in onset and progression.4 5 6 7 8 Recently, however, inflammatory mechanisms and immune activation have been hypothesized to play a role in the pathogenesis of this disease.9 Several studies have identified the presence of macrophages within CNV,10 11 12 but no experimental confirmation has been provided to confirm the pathogenic involvement of these cells to formation or severity of CNV.

Selective depletion of macrophages in vivo can be achieved with dichloromethylene diphosphonate-liposomes (CL2MDP-lip).13 The liposomes are ingested by the macrophages, which are then destroyed after phospholipase-mediated disruption of the liposome and intracellular release of CL2MDP. The exact mechanism of macrophage depletion by intracellular accumulation of CL2MDP-lip is unknown, but it is believed that the intralysosomal accumulation of CL2MDP generates signals to induce macrophage apoptosis.14 The purpose of this study was to determine whether macrophage depletion by CL2MDP diminishes the severity of experimental CNV. Our results indicate that macrophage depletion in aged-mice decreased the severity of CNV, with the decrease defined as smaller vascular and cellular surface area and less vascularity, in an experimental model of laser CNV.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Mice
Mice used in this study were handled in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Twenty-four female, normal C57BL/6 mice aged 16 months (n = 22, weight, 25–30 g), at the onset of the study, were purchased from the National Institute on Aging (Bethesda, MD). Also, seven BALB/c retired breeders were used for the immunostaining protocol, because uveal tract wholemount preparations are more informative when applied to albino animals in which uveal tissues are sufficiently thin and transparent to allow transillumination and resolution of individual stained cells.

Preparation of CL2MDP-lip
CL2MDP-lip was prepared 13 by dissolving 1,2 dioleolyl-sn-glycero-3-phosphocholine and cholesterol (both from Avanti Polar Lipids, Alabaster, AL) in a mixture of methanol and chloroform (1:1). After low-vacuum rotary evaporation at 37°C to remove the organic phase, the lipids were mixed with clodronic acid (1.9 g) dissolved in phosphate-buffered saline (0.6 M). They were allowed to sit at room temperature for 2 hours in a nitrogen-purged chamber to induce liposome swelling. Resuspension of liposomes was achieved by water sonication at room temperature for 3 minutes. The resultant liposomes were washed at 10,000g to 100,000g in an ultracentrifuge twice for 30 minutes at 16°C. The milky liposomes were removed gently with a pipette, resuspended in 4 mL of sterilized PBS, and stored in a nitrogen chamber for up to 1 week. For the PBS-liposomes the lipids were mixed with sterilized PBS.

Macrophage Depletion
Mice were anesthetized with an intramuscular administration of ketamine hydrochloride (42.8 mg/kg), xylazine (8.5 mg/kg), and acepromazine (1.4 mg/kg). Splenic and systemic macrophage depletion (C57BL/6 mice, n = 8) was performed with CL2MDP-lip (200 µL = 1 mg) by intraperitoneal (IP) administration 4 days and 24 hours before the laser procedure and afterward every 2 to 3 days for 2 weeks. Macrophage depletion from draining lymph nodes located at the level of the submandibular, axillary, and inguinal regions was performed bilaterally by injecting subcutaneous (SC) CL2MDP-lip (50 µL = 0.25 mg) 24 hours before laser application and afterward every 2 to 3 days for 2 weeks. Control groups (C57BL/6 mice, n = 8 each) received IP and SC administration of PBS alone or PBS-liposomes injections.15 16 17

Choroidal Flatmount Preparation and Immunostaining Protocol
Briefly, whole-body perfusion was performed with (1x) PBS+K3 EDTA (1.7 mg/mL) followed with fixation with 4% paraformaldehyde. Enucleation of the eyes was performed, and removal of the anterior segment and neurosensory retina was performed after fixation. The remaining eye cup was placed on a glass slide, and three to four relaxing incisions were made through the optic disc, leaving three to four pieces of choroid and sclera, respectively. The choroid was separated from the underlying sclera with a Beaver blade no. 64.18 The choroid was permeabilized and hydrated. F4/80 antibodies (10 µg/mL MCA497R; Serotec, Raleigh, NC) were used, followed by incubation with a secondary biotinylated antirat antibody (ABC Kit; Vector Laboratories, Burlingame, CA). A peroxidase substrate (Vector VIP, Vector Laboratories) was used until the reactions in the binding sites were developed to the desired intensity. Macrophage density morphometry was performed after digitizing the choroidal flatmount preparations with a light microscope (x400 magnification) connected to a color video camera and a frame grabber. Three representative sections were analyzed at high-power magnification per piece of choroidal tissue, and the results were averaged with those in the remainder of the pieces to obtain the density of macrophages per eye. This was compared between macrophage-depleted animals (BALB/c, n = 3) and the control (BALB/c, n = 4; PBS or PBS-liposomes).

Monocyte Isolation and Flow Cytometric Evaluation
Briefly, white blood cells were separated from EDTA-anticoagulated whole blood by gradient separation technique.19 For flow cytometry, the monocytes were labeled with a rat anti-mouse F4/80 antigen-FITC conjugate (10 µg/mL MCA497F; Serotec). Cells were prepared for analysis in flow cytometer using digitonin (1 mg/mL) and propidium iodide (PI, 500 µg/mL) modified from previous publications.20

Laser treatment, fluorescein angiography, histology, and flatmount preparation and analysis were performed as described in an earlier published study.1

Statistical Analysis
Morphometric data for different lesions in each eye were averaged to provide one value per eye. The mean ± SD of these measures for each group was calculated and probabilities (t-test) were obtained on computer (Prism, ver. 3.0; GraphPad, San Diego, CA). P < 0.05 was considered statistically significant in all forms of statistical analysis used.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
First, we confirmed that CL2MDP-lip treatment adequately depleted circulating monocytes and choroidal macrophages. Flow cytometry was used to determine the degree of depletion of circulating monocytes. The total leukocyte population isolated from whole blood was stained for F4/80, a mouse macrophage-specific marker. Because monocytes constitute only 2% to 8% of total blood leukocytes, we enriched the sample for monocytes by using flow cytometry to identify the subset of large leukocytes (consisting of monocytes and large granular lymphocytes). Within this subset, leukocytes from mice treated with PBS or PBS-liposomes typically demonstrated approximately 60% positivity for F4/80. In contrast, CL2-MDP-lip treatment reduced the percentage of F4/80-positive cells to 15%, indicating a reduction of approximately 75% (Fig. 1) .



View larger version (30K):
[in this window]
[in a new window]
  		FIGURE 1. Flow cytometry of white blood cells obtained from mouse blood. (A) Dual light-scatter characteristics for the gated population of macrophages and large lymphocytes. Acquisition gates were set to detect only the PI fluorescence-positive events from a cell suspension in which no antibody staining was used. (B–D) Positive staining of blood monocytes in the gated population after labeling them with the macrophage marker F4/80 after treatment with PBS (B), PBS-liposomes (C), or CL2MDP-lip (D). CL2MDP-lip–treated mouse showed depletion of monocytes to 15%.

 
Treatment with CL2-MDP-lip also depleted choroidal macrophages in normal eyes before laser-induced CNV (Fig. 2) . Choroidal flatmount preparations were immunostained with anti-F4/80. CL2-MDP-lip–treated mice showed a 46% reduction in the density of choroidal macrophages compared with control mice (9.6 ± 0.4 vs. 5.2 ± 1.8 macrophages per high-power field with P < 0.028).



View larger version (76K):
[in this window]
[in a new window]
  		FIGURE 2. Choroidal flatmount preparations from BALB/c mouse for detection of choroidal macrophages using anti-F4/80 staining. (A) Choroidal macrophage density in a control mouse compared with the diminished density of macrophages (B) in which the animals received treatment with CL2MDP-lip for 2 weeks. Magnification, x400.

 
Comparisons of fluorescein angiograms between macrophage-depleted and control mice revealed that treated mice had a smaller area of early hyperfluorescence and a much smaller area and intensity of late fluorescein leakage, indicating that the formation of CNV was less severe in treated animals (Fig. 3) . However, the frequency of individual lesions with evident fluorescein leakage was equivalent in both groups, indicating that macrophage treatment did not prevent formation of CNV.



View larger version (50K):
[in this window]
[in a new window]
  		FIGURE 3. Fluorescein angiograms of eyes obtained 2 weeks after diode laser photocoagulation to induce CNV. (A–C) angiogram of a control (PBS treated) animal. (A) A pointlike hyperfluorescent area that greatly increased in size and intensity, as shown in (B) and (C). There was intense leakage in the late phases (1- and 5-minute frames, respectively corresponding to intermediate [B] and late [C] phases) of the angiogram which shows the severity of the CNV lesion. (D–F) Fluorescein angiogram of a treated (CL2MDP-lip) animal. A similar angiographic pattern can be seen but the intensity and the size of the hyperfluorescent lesion is smaller. (D) Depicts the initial phase of the angiogram in which a pointlike hyperfluorescence is evident, which grows moderately in size and intensity during intermediate (E) and late (F) phases of the angiogram.

 
Histopathology confirmed that CNV in control mice revealed a much larger diameter and thicker center, which was confirmed with quantitative analysis (Fig. 4) . Morphologic features of CNV between macrophage depleted and nondepleted mice were similar.



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 4. Quantitative analysis of histopathology sections. (A) Maximum lesion diameter (measured in pixels) in which the CL2MDP-lip treated group shows significantly smaller diameter than the control group (P < 0.0006). (B) Maximum lesion thickness (measured in pixels) in which the CL2MDP-liposomes treated group shows a significantly lesser lesion thickness than the control group (P < 0.03). *Statistically significant difference.

 
Flatmount analysis better demonstrated the decreased size, vascularity, and cellularity in CNV from mice depleted of macrophages (Fig. 5) . CNV (defined as a surface area >0.5 disc areas) was observed in 84 (100%) of the lesions induced in 16-month-old animals of any group studied. As reported previously, CNV lesions reached maximum size within 14 days. CNV in mice that served as the control were large, with irregular borders and extensions. As shown previously, in aged (i.e., 16 month old) macrophage-intact mice, CNV from different laser spots often became confluent. (Figs. 5A 5B) . In contrast, macrophage-depleted mice demonstrated much smaller lesions, typically maintaining four small discrete circular lesions with poorly defined margins (Figs. 5C 5D) . A reduction of surface area was observed when compared with the PBS (by 50.8%) and PBS-liposome–treated groups (by 33.75%).



View larger version (85K):
[in this window]
[in a new window]
  		FIGURE 5. Flatmount preparations of the posterior pole of a mouse eye using FITC-dextran and PI stains 2 weeks after diode laser photocoagulation. (A, B) Vascularity and cellularity of the lesions of the control group. CNV lesions were large and with irregular borders. (C, D) Small discrete circular lesions (dotted circles) of the CL2MDP-lip–treated animals. The size, vascularity, and cellularity of the lesions were less in the macrophage-depleted mice (Fig. 6) . D, optic disc.

 
The relative vascularity of CNV was calculated by measuring the ratio of FITC fluorescence in the lesion, compared with the background choroid (Fig. 6) . The margins of the lesion outlined by propidium fluorescence (i.e., cell nuclei) were slightly larger than the margins by FITC, suggesting the presence of more avascular cellular growth at the margins of the CNV (Figs. 6A 6C) . The data showed a significantly lesser vascular luminosity index in mice that were macrophage depleted (Fig. 6B) .



View larger version (30K):
[in this window]
[in a new window]
  		FIGURE 6. Quantitative analysis of flatmount specimens, showing that CL2MDP-lip–treated animals had significantly less severe CNV lesions when measured with FITC and PI staining. (A) Vascular margins (as measured in disc areas) of the lesions in both the control and the treated mice. Compared with control animals, analysis of flatmounted retinas of macrophage depleted mice demonstrated significant reduction in size of CNV lesions (2.8 ± 0.5 DA vs. 1.4 ± 0.1 DA, P < 0.043). (B) Vascular luminosity index. The treated group also revealed less vascularity of CNV lesions (1.6 ± 0.1 units vs. 1.1 ± 0.0 units, P < 0.0092). (C) Cellular margins (size), measured in DAs in which the treated group also showed a decrease in size compared with the nontreated one (3.3 ± 0.6 DA vs. 1.7 ± 0.1 DA, P < 0.04). (D) Cell density was reported as the cell-density index, which was not significantly different between groups. Nevertheless, the total cellular component of the depleted animals was less due to the decrease in size of the CNV. *Statistically significant difference.

 
We also evaluated the cell density in CNV by measuring the ratio of fluorescence luminosity from the PI nuclear staining in the lesion compared with the background choroid. This cellular density index was not significantly different in the macrophage-depleted mice, in part because the cells involved in CNV formation in both control and macrophage-depleted groups may represent different cell types. More specifically, these cells could represent pericytes, fibroblasts, and endothelial cells that were not affected by the depletion of macrophages (Fig. 6D) .


   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
Macrophages in tissues are derived from circulating blood monocytes. Within tissue they undergo maturation, adaptation to their local microenvironment, and differentiation into various types of cells that perform specific housekeeping, trophic, and immunologic functions. Macrophages play an important role in pathogen recognition and clearance, as well as scavenging of senescent and dying cells. They also function as antigen-presenting cells for T lymphocytes and as inflammatory effector cells. Several different stages of metabolic and functional activities, which in turn, represent different programs of gene activation are often described, including scavenging and activated macrophages.21 Activated macrophages are most efficient at synthesizing and releasing mediators to amplify inflammation and can mediate chronic injury leading to processes such as fibrosis, wound repair, extracellular matrix turnover, and angiogenesis.22 23

In studies using rats, macrophage subpopulations are better delineated by monoclonal antibodies.24 The ED-1 positive, blood-derived macrophage population represents short-lived cells with high turnover that are recent recruits to tissues. These cells are thought to serve inflammatory and scavenging functions. In contrast, the ED-2 tissue-resident subset comprises relatively long-lived cells with low turnover and long duration in tissues. These cells are thought to serve trophic and tissue-maintenance functions.25 Dendritic cells are specialized noninflammatory monocytes that present antigen to naïve T cells.26

The normal choroid is richly invested with various subsets of monocytes and macrophages, including blood-derived macrophages, tissue-resident macrophages and dendritic cells.27 28 However, monocytes and macrophages are difficult to evaluate by histology in normal or diseased choroid, because they acquire flattened profiles that cause them to be difficult to demonstrate on routine histologic sections. Nevertheless, they are presumed to serve similar functions in the choroid, as described in other tissues.

Grindle and Marshall29 were probably the first to postulate a role for macrophages in the pathogenesis of AMD. Penfold et al.30 31 subsequently showed the involvement of low-grade chronic inflammatory cell infiltration in AMD, and Sarks et al.32 and Penfold et al.33 reported macrophages and giant cells in association with Bruch’s membrane, geographic atrophy, and CNV. Most recently, Anderson et al.34 have suggested that many large drusen appear to contain a central core derived from a choroidal monocyte, perhaps representing a dendritic cell.

Many investigators have suggested that macrophages might be a stimulus for CNV and a common factor linking the diverse diseases associated with CNV.35 Grossniklaus et al.10 36 have demonstrated significant macrophage infiltration in specimens of surgically excised CNV and that these cells appear to be synthesizing various cytokines and growth factors. In a primate model for laser-induced experimental subretinal neovascularization, Ishibashi et al.37 showed that macrophages migrate into the laser wounds and seemed to contribute to the neovascular response. Finally, ocular corticosteroid therapy has been used in the treatment of CNV. Although corticosteroids inhibit many cellular processes they are potent modulators of macrophage functions. These studies38 39 40 suggest that more research is needed to explore the therapeutic potential of nonspecific anti-inflammatory therapy in AMD. Specifically, triamcinolone acetate has been used to treat CNV lesions, based on research in which these drugs have the potential to influence cellular permeability and downregulate the expression of inflammatory markers.41 42 Taken together, these observations imply a potential pathogenic role for cytokines, chemical mediators, matrix metalloproteinases, mitogens, or angiogenic factors released by macrophages from the choroid.10 12

In this study, we evaluated the effect of macrophage depletion on the severity of experimental CNV in aged (16 months) old mice. Aging has been shown to increase the severity of CNV lesions in mice.1 We found that CNV in macrophage-depleted mice were smaller, thinner, less cellular, and less vascularized than nondepleted mice but did not decrease the incidence of CNV. However, we did not observe a difference in the cell density or frequency of actively leaking lesions between compared groups. Nevertheless, the total cellular component of the depleted animals was less because of the decrease in size of the CNV.

The effective depletion of macrophages was confirmed by flow cytometry of circulating monocytes and microscopic examination of choroidal flatmount preparations for choroidal macrophages. Different percentages of depletion were determined with the two analyses. The level of depletion of blood monocytes achieved in our study was consisted with published results (70%–95%).17 43 In other studies of nonocular tissues, depletion of tissue macrophages by clodronate has been more variable. The ED-1–positive, blood-derived macrophage population appears more susceptible to depletion by clodronate than do the ED-2–positive tissue-resident macrophages.44 45 Our findings seem to concur, because circulating monocytes were 75% depleted, but choroidal macrophages were only reduced by 46%. We presume that the residual choroidal macrophages represent mostly tissue-resident macrophages. If true, then our results suggest that the blood derived circulating monocytes are more likely to contribute to CNV pathogenesis.

PBS alone and PBS-liposome–treated animals were used as control subjects for completeness. Empty liposomes, in common with other particulate compounds, may influence macrophage biology and must be used as a specificity control when liposomes are used as a drug delivery method for specific agents. However, as stated by investigators who developed this procedure, the best control for studies in which general macrophage depletion is required (as in our study) are PBS sham injections. This control would represent normal, healthy, nonblocked, nonsuppressed, and nonstimulated macrophages.13

Recent data from several groups suggest that innate immune mechanisms and localized choroidal inflammation may generally contribute to the pathogenesis of AMD. In addition to macrophages, other relevant innate immune mechanisms involved in AMD pathogenesis include injurious stimuli (oxidants or infectious agents) and amplification cascades (such as complement, mediators systems, and cytokines). For example, Anderson et al.34 have identified complement and immune complexes in association with nodular drusen, which are potentially at high risk for CNV formation.34 Perhaps immune complexes are stimuli for the recruitment of macrophages or monocytes in human AMD.


   Footnotes
 
Presented in part at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, May 2002.

Supported by National Eye Institute Grant EY/AI 13318.

Submitted for publication January 14, 2003; revised February 28, 2003; accepted March 18, 2003.

Disclosure: D.G. Espinosa-Heidmann, None; I.J. Suner, None; E.P. Hernandez, None; D. Monroy, None; K.G. Csaky, None; S.W. Cousins, None

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Corresponding author: Scott W. Cousins, Bascom Palmer Eye Institute, William L., McKnight Vision Research Center, 1638 N.W. 10th Avenue, Miami, FL 33136; scousins{at}med.miami.edu.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Espinosa-Heidmann, DG, Suner, I, Hernandez, EP, Frazier, WD, Csaky, KG, Cousins, SW. (2002) Age as an independent risk factor for severity of experimental choroidal neovascularization Invest Ophthalmol Vis Sci 43,1567-1573[Abstract/Free Full Text]
  2. Spaide, RF. (1999) Choroidal neovascularization in younger patients Curr Opin Ophthalmol 10,177-181[CrossRef][Medline][Order article via Infotrieve]
  3. Bressler, NM, Bressler, SB, Fine, SL. (1988) Age-related macular degeneration Surv Ophthalmol 32,375-413[CrossRef][Medline][Order article via Infotrieve]
  4. Evans, JR. (2001) Risk factors for age-related macular degeneration Prog Retinal Eye Res 20,227-253[CrossRef][Medline][Order article via Infotrieve]
  5. Hawkins, BS, Bird, A, Klein, R, West, SK. (1999) Epidemiology of age-related macular degeneration Mol Vis 5,26[Medline][Order article via Infotrieve]
  6. la Cour, M, Kiilgaard, JF, Nissen, MH. (2002) Age-related macular degeneration: epidemiology and optimal treatment Drugs Aging 19,101-133[CrossRef][Medline][Order article via Infotrieve]
  7. Husain, D, Ambati, B, Adamis, AP, Miller, JW. (2002) Mechanisms of age-related macular degeneration Ophthalmol Clin North Am 15,87-91[CrossRef][Medline][Order article via Infotrieve]
  8. Yates, JR, Moore, AT. (2000) Genetic susceptibility to age related macular degeneration J Med Genet 37,83-87[Abstract/Free Full Text]
  9. Penfold, PL, Madigan, MC, Gillies, MC, Provis, JM. (2001) Immunological and aetiological aspects of macular degeneration Prog Retinal Eye Res 20,385-414[CrossRef][Medline][Order article via Infotrieve]
  10. Grossniklaus, HE, Ling, JX, Wallace, TM, et al (2002) Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization Mol Vis 8,119-126[Medline][Order article via Infotrieve]
  11. Yi, X, Takahashi, K, Ogata, N, Uyama, M. (1996) Immunohistochemical proof of origin of macrophages in laser photocoagulation lesion in the retina Jpn J Ophthalmol 40,192-201[Medline][Order article via Infotrieve]
  12. Oh, H, Takagi, H, Takagi, C, et al (1999) The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes Invest Ophthalmol Vis Sci 40,1891-1898[Abstract/Free Full Text]
  13. Van Rooijen, N, Sanders, A. (1993) Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications J Immunol Meth 174,83-93
  14. Naito, M, Nagai, H, Kawano, S, et al (1996) Liposome-encapsulated dichloromethylene diphosphonate induces macrophage apoptosis in vivo and in vitro J Leukoc Biol 60,337-344[Abstract]
  15. Bauer, D, Mrzyk, S, Van Rooijen, N, Steuhl, KP, Heiligenhaus, A. (2001) Incidence and severity of herpetic stromal keratitis: impaired by the depletion of lymph node macrophages Exp Eye Res 72,261-269[CrossRef][Medline][Order article via Infotrieve]
  16. Biewenga, J, van der Ende, MB, Krist, LF, Borst, A, Ghufron, M, Van Rooijen, N. (1995) Macrophage depletion in the rat after intraperitoneal administration of liposome-encapsulated clodronate: depletion kinetics and accelerated repopulation of peritoneal and omental macrophages by administration of Freund’s adjuvant Cell Tissue Res 280,189-196[Medline][Order article via Infotrieve]
  17. Nieuwenhuijzen, GA, Knapen, MF, Hendriks, T, Van Rooijen, N, Goris, RJ. (1997) Elimination of various subpopulations of macrophages and the development of multiple-organ dysfunction syndrome in mice Arch Surg 132,533-539[Abstract/Free Full Text]
  18. McMenamin, PG. (2000) Optimal methods for preparation and immunostaining of iris, ciliary body, and choroidal wholemounts Invest Ophthalmol Vis Sci 41,3043-3048[Abstract/Free Full Text]
  19. Cramer, R, Dri, P, Zabucchi, G, Patriarca, P. (1992) A simple and rapid method for isolation of eosinophilic granulocytes from human blood J Leukoc Biol 52,331-335[Abstract]
  20. Cousins, SW, Streilein, JW. (1990) Flow cytometric detection of lymphocyte proliferation in eyes with immunogenic inflammation Invest Ophthalmol Vis Sci 31,2111-2122[Abstract/Free Full Text]
  21. Cousins, SW, Csaky, KG. (2002) Immunology of age-related macular degeneration Lim, JI eds. Age-Related Macular Degeneration ,27-65 Marcel Dekker, Inc New York.
  22. Sunderkotter, C, Steinbrink, K, Goebeler, M, Bhardwaj, R, Sorg, C. (1994) Macrophages and angiogenesis J Leukoc Biol 55,410-422[Abstract]
  23. Leibovich, SJ, Polverini, PJ, Shepard, HM, Wiseman, DM, Shively, V, Nuseir, N. (1987) Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha Nature 329,630-632[CrossRef][Medline][Order article via Infotrieve]
  24. Dijkstra, CD, Dopp, EA, Joling, P, Kraal, G. (1985) The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3 Immunology 54,589-599[Medline][Order article via Infotrieve]
  25. Hume, DA, Ross, IL, Himes, SR, Sasmono, RT, Wells, CA, Ravasi, T. (2002) The mononuclear phagocyte system revisited J Leukoc Biol 72,621-627[Abstract/Free Full Text]
  26. Gluckman, JC, Canque, B, Rosenzwajg, M. (2002) Dendritic cells: a complex simplicity Transplantation 73(suppl 1),S3-S6
  27. McMenamin, PG. (1997) The distribution of immune cells in the uveal tract of the normal eye Eye 11,183-193
  28. McMenamin, PG. (1999) Dendritic cells and macrophages in the uveal tract of the normal mouse eye Br J Ophthalmol 83,598-604[Abstract/Free Full Text]
  29. Grindle, CF, Marshall, J. (1978) Ageing changes in Bruch’s membrane and their functional implications Trans Ophthalmol Soc UK 98,172-175[Medline][Order article via Infotrieve]
  30. Penfold, PL, Killingsworth, MC, Sarks, SH. (1985) Senile macular degeneration: the involvement of immunocompetent cells Graefes Arch Clin Exp Ophthalmol 223,69-76[CrossRef][Medline][Order article via Infotrieve]
  31. Penfold, P, Killingsworth, M, Sarks, S. (1984) An ultrastructural study of the role of leucocytes and fibroblasts in the breakdown of Bruch’s membrane Aust J Ophthalmol 12,23-31[Medline][Order article via Infotrieve]
  32. Sarks, SH, Van Driel, D, Maxwell, L, Killingsworth, M. (1980) Softening of drusen and subretinal neovascularization Trans Ophthalmol Soc UK 100,414-422[Medline][Order article via Infotrieve]
  33. Penfold, PL, Killingsworth, MC, Sarks, SH. (1986) Senile macular degeneration. The involvement of giant cells in atrophy of the retinal pigment epithelium Invest Ophthalmol Vis Sci 27,364-371[Abstract/Free Full Text]
  34. Anderson, DH, Mullins, RF, Hageman, GS, Johnson, LV. (2002) A role for local inflammation in the formation of drusen in the aging eye Am J Ophthalmol 134,411-431[CrossRef][Medline][Order article via Infotrieve]
  35. Pollack, A, Korte, GE, Heriot, WJ, Henkind, P. (1986) Ultrastructure of Bruch’s membrane after krypton laser photocoagulation. II. Repair of Bruch’s membrane and the role of macrophages Arch Ophthalmol 104,1377-1382[Abstract/Free Full Text]
  36. Grossniklaus, HE, Cingle, KA, Yoon, YD, Ketkar, N, L’Hernault, N, Brown, S. (2000) Correlation of histologic 2-dimensional reconstruction and confocal scanning laser microscopic imaging of choroidal neovascularization in eyes with age-related maculopathy Arch Ophthalmol 118,625-629[Abstract/Free Full Text]
  37. Ishibashi, T, Miki, K, Sorgente, N, Patterson, R, Ryan, SJ. (1985) Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate Arch Ophthalmol 103,708-711[Abstract/Free Full Text]
  38. Danis, RP, Ciulla, TA, Pratt, LM, Anliker, W. (2000) Intravitreal triamcinolone acetonide in exudative age-related macular degeneration Retina 20,244-250[CrossRef][Medline][Order article via Infotrieve]
  39. Challa, JK, Gillies, MC, Penfold, PL, Gyory, JF, Hunyor, AB, Billson, FA. (1998) Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up Aust NZ J Ophthalmol 26,277-281[Medline][Order article via Infotrieve]
  40. Ciulla, TA, Criswell, MH, Danis, RP, Hill, TE. (2001) Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model Arch Ophthalmol 119,399-404[Abstract/Free Full Text]
  41. Penfold, PL, Wen, L, Madigan, MC, Gillies, MC, King, NJ, Provis, JM. (2000) Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration Clin Exp Immunol 121,458-465[CrossRef][Medline][Order article via Infotrieve]
  42. Penfold, PL, Wong, JG, Gyory, J, Billson, FA. (2001) Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration Clin Experiment Ophthalmol 29,188-192[CrossRef][Medline][Order article via Infotrieve]
  43. Roscic-Mrkic, B, Schwendener, RA, Odermatt, B, et al (2001) Roles of macrophages in measles virus infection of genetically modified mice J Virol 75,3343-3351[Abstract/Free Full Text]
  44. Pouvreau, I, Zech, JC, Thillaye-Goldenberg, B, Naud, MC, Van Rooijen, N, de Kozak, Y. (1998) Effect of macrophage depletion by liposomes containing dichloromethylene-diphosphonate on endotoxin-induced uveitis J Neuroimmunol 86,171-181[CrossRef][Medline][Order article via Infotrieve]
  45. Forrester, JV, Huitinga, I, Lumsden, L, Dijkstra, CD. (1998) Marrow-derived activated macrophages are required during the effector phase of experimental autoimmune uveoretinitis in rats Curr Eye Res 17,426-437[Medline][Order article via Infotrieve]



This article has been cited by other articles:


Home page
 Arch OphthalmolHome page
O. Tatar, A. Adam, K. Shinoda, E. Kaiserling, V. Boeyden, C. Claes, C. Eckardt, T. Eckert, G. Pertile, G. B. Scharioth, et al.
Early Effects of Intravitreal Triamcinolone Acetonide on Inflammation and Proliferation in Human Choroidal Neovascularization
Arch Ophthalmol, March 1, 2009; 127(3): 275 - 281.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
J. J. Wang, E. Rochtchina, W. Smith, R. Klein, B. E. K. Klein, T. Joshi, T. A. Sivakumaran, S. Iyengar, and P. Mitchell
Combined Effects of Complement Factor H Genotypes, Fish Consumption, and Inflammatory Markers on Long-Term Risk for Age-related Macular Degeneration in a Cohort
Am. J. Epidemiol., March 1, 2009; 169(5): 633 - 641.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
O Tatar, K Shinoda, E Kaiserling, C Claes, C Eckardt, T Eckert, G Pertile, V Boeyden, G B Scharioth, E Yoeruek, et al.
Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularisation
Br. J. Ophthalmol., February 1, 2009; 93(2): 159 - 165.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
F. Schroedl, A. Brehmer, W. L. Neuhuber, F. E. Kruse, C. A. May, and C. Cursiefen
The Normal Human Choroid Is Endowed with a Significant Number of Lymphatic Vessel Endothelial Hyaluronate Receptor 1 (LYVE-1)-Positive Macrophages
Invest. Ophthalmol. Vis. Sci., December 1, 2008; 49(12): 5222 - 5229.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. Satofuka, A. Ichihara, N. Nagai, K. Noda, Y. Ozawa, A. Fukamizu, K. Tsubota, H. Itoh, Y. Oike, and S. Ishida
(Pro)renin Receptor Promotes Choroidal Neovascularization by Activating Its Signal Transduction and Tissue Renin-Angiotensin System
Am. J. Pathol., December 1, 2008; 173(6): 1911 - 1918.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
S.-C. Su, E. A. Mendoza, H.-i. Kwak, and K. J. Bayless
Molecular profile of endothelial invasion of three-dimensional collagen matrices: insights into angiogenic sprout induction in wound healing
Am J Physiol Cell Physiol, November 1, 2008; 295(5): C1215 - C1229.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M. H. Davies, A. J. Stempel, and M. R. Powers
MCP-1 Deficiency Delays Regression of Pathologic Retinal Neovascularization in a Model of Ischemic Retinopathy
Invest. Ophthalmol. Vis. Sci., September 1, 2008; 49(9): 4195 - 4202.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
K. Nakai, O. Fainaru, L. Bazinet, P. Pakneshan, O. Benny, E. Pravda, J. Folkman, and R. J. D'Amato
Dendritic Cells Augment Choroidal Neovascularization
Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3666 - 3670.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
K. Noda, H. She, T. Nakazawa, T. Hisatomi, S. Nakao, L. Almulki, S. Zandi, S. Miyahara, Y. Ito, K. L. Thomas, et al.
Vascular adhesion protein-1 blockade suppresses choroidal neovascularization
FASEB J, August 1, 2008; 22(8): 2928 - 2935.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
M-K Ezzat, C R Hann, S Vuk-Pavlovic, and J S Pulido
Immune cells in the human choroid
Br. J. Ophthalmol., July 1, 2008; 92(7): 976 - 980.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
O. Tatar, E. Yoeruek, P. Szurman, K. U. Bartz-Schmidt, A. Adam, K. Shinoda, C. Eckardt, V. Boeyden, C. Claes, G. Pertile, et al.
Effect of Bevacizumab on Inflammation and Proliferation in Human Choroidal Neovascularization
Arch Ophthalmol, June 1, 2008; 126(6): 782 - 790.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
K. Izumi-Nagai, N. Nagai, K. Ohgami, S. Satofuka, Y. Ozawa, K. Tsubota, S. Ohno, Y. Oike, and S. Ishida
Inhibition of Choroidal Neovascularization with an Anti-Inflammatory Carotenoid Astaxanthin
Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1679 - 1685.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Lu, L. Li, K. Kuno, Y. Wu, T. Baba, Y.-y. Li, X. Zhang, and N. Mukaida
Protective Roles of the Fractalkine/CX3CL1-CX3CR1 Interactions in Alkali-Induced Corneal Neovascularization through Enhanced Antiangiogenic Factor Expression
J. Immunol., March 15, 2008; 180(6): 4283 - 4291.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
S. Qin, M. Ni, and G. W. De Vries
Implication of S-Adenosylhomocysteine Hydrolase in Inhibition of TNF-{alpha}- and IL-1{beta}-Induced Expression of Inflammatory Mediators by AICAR in RPE Cells
Invest. Ophthalmol. Vis. Sci., March 1, 2008; 49(3): 1274 - 1281.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
S. Rao, I. B. Lobov, J. E. Vallance, K. Tsujikawa, I. Shiojima, S. Akunuru, K. Walsh, L. E. Benjamin, and R. A. Lang
Obligatory participation of macrophages in an angiopoietin 2-mediated cell death switch
Development, December 15, 2007; 134(24): 4449 - 4458.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
T. Nagai, H. Imai, S. Honda, and A. Negi
Antiangiogenic Effects of Bisphosphonates on Laser-Induced Choroidal Neovascularization in Mice
Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5716 - 5721.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
T. Koto, N. Nagai, H. Mochimaru, T. Kurihara, K. Izumi-Nagai, S. Satofuka, H. Shinoda, K. Noda, Y. Ozawa, M. Inoue, et al.
Eicosapentaenoic Acid Is Anti-Inflammatory in Preventing Choroidal Neovascularization in Mice
Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4328 - 4334.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. Izumi-Nagai, N. Nagai, Y. Ozawa, M. Mihara, Y. Ohsugi, T. Kurihara, T. Koto, S. Satofuka, M. Inoue, K. Tsubota, et al.
Interleukin-6 Receptor-Mediated Activation of Signal Transducer and Activator of Transcription-3 (STAT3) Promotes Choroidal Neovascularization
Am. J. Pathol., June 1, 2007; 170(6): 2149 - 2158.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
A. Giovannini, P. Neri, L. Mercanti, and C. Brue
Photodynamic treatment versus photodynamic treatment associated with systemic steroids for idiopathic choroidal neovascularisation
Br. J. Ophthalmol., May 1, 2007; 91(5): 620 - 623.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M. Kamei, K. Yoneda, N. Kume, M. Suzuki, H. Itabe, K.-i. Matsuda, T. Shimaoka, M. Minami, S. Yonehara, T. Kita, et al.
Scavenger Receptors for Oxidized Lipoprotein in Age-Related Macular Degeneration
Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1801 - 1807.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
P. Zamiri, S. Masli, J. W. Streilein, and A. W. Taylor
Pigment epithelial growth factor suppresses inflammation by modulating macrophage activation.
Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 3912 - 3918.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. S. Hageman, D. H. Anderson, L. V. Johnson, L. S. Hancox, A. J. Taiber, L. I. Hardisty, J. L. Hageman, H. A. Stockman, J. D. Borchardt, K. M. Gehrs, et al.
From The Cover: A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration
PNAS, May 17, 2005; 102(20): 7227 - 7232.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
S. Matsuda, F. Gomi, Y. Oshima, M. Tohyama, and Y. Tano
Vascular Endothelial Growth Factor Reduced and Connective Tissue Growth Factor Induced by Triamcinolone in ARPE19 Cells under Oxidative Stress
Invest. Ophthalmol. Vis. Sci., March 1, 2005; 46(3): 1062 - 1068.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
R. S. Apte, R. A. Barreiro, E. Duh, O. Volpert, and T. A. Ferguson
Stimulation of Neovascularization by the Anti-angiogenic Factor PEDF
Invest. Ophthalmol. Vis. Sci., December 1, 2004; 45(12): 4491 - 4497.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
C Tsutsumi-Miyahara, K-H Sonoda, K Egashira, M Ishibashi, H Qiao, T Oshima, T Murata, M Miyazaki, I F Charo, S Hamano, et al.
The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularisation
Br. J. Ophthalmol., September 1, 2004; 88(9): 1217 - 1222.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
S. W. Cousins, D. G. Espinosa-Heidmann, and K. G. Csaky
Monocyte Activation in Patients With Age-Related Macular Degeneration: A Biomarker of Risk for Choroidal Neovascularization?
Arch Ophthalmol, July 1, 2004; 122(7): 1013 - 1018.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
D. G. Espinosa-Heidmann, A. Caicedo, E. P. Hernandez, K. G. Csaky, and S. W. Cousins
Bone Marrow-Derived Progenitor Cells Contribute to Experimental Choroidal Neovascularization
Invest. Ophthalmol. Vis. Sci., November 1, 2003; 44(11): 4914 - 4919.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Espinosa-Heidmann, D. G.
Right arrow Articles by Cousins, S. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Espinosa-Heidmann, D. G.
Right arrow Articles by Cousins, S. W.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS